Latest Biotech News

Global X Management (AUS) Limited has announced estimated distributions for over 30 ETFs for the period ending 30 June 2026, all eligible for reinvestment via its Distribution Reinvestment Plan (DRP). The announcement outlines key dates for investors to act on their DRP elections and highlights the wide range of income levels across its funds.

Skin Elements Limited has secured a $900,000 placement at a 25% discount to recent prices, bolstering its balance sheet to advance its natural biotechnology product range. The company also appointed Rod Nicholas as non-executive chairman and engaged Phoenix Global Investments for investor relations.

Memphasys has rapidly established a foothold in the UK IVF market, securing four active commercial trials and initial orders for its Felix™ sperm selection system within weeks of launch. This momentum aligns with its global expansion strategy targeting major fertility markets.

Cynata Therapeutics (ASX: CYP) has had its trading suspension lifted immediately following the publication of results from its Phase 3 Osteoarthritis and Phase 2 Graft versus Host Disease clinical trials.

Syntara Limited has completed a $0.84 million Share Purchase Plan, boosting its total capital raise to $8.84 million to fund multiple clinical trials and patent development through to Q3 2027.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Immuron Limited has responded to an ASX price query following a sharp rise in its share price and trading volume, confirming no undisclosed information but pointing to a recent CEO presentation as a possible driver.

Nexalis Therapeutics (ASX: NX1) has voluntarily suspended trading of its shares pending a material announcement on its existing debt funding facility, extending a recent trading halt. The suspension is set to last until the earlier of the announcement release or resumption of trading on 28 May 2026.

Vectus Biosystems has secured $791,000 through a placement to accelerate its lead fibrosis drug VB0004's Phase IB clinical trial and advance other drug candidates.

Syntara Limited offers existing shareholders a discounted share purchase plan to raise about $2 million, following a recent $8 million institutional placement to fund clinical trials and licensing.

Neurizon Therapeutics has gained ethics approval to start a Phase 1 trial of its NUZ-001 oral liquid formulation, aiming to ease treatment for ALS patients with swallowing difficulties.

Vectus Biosystems appoints Dr Tara Speranza as CEO and CTO to accelerate development of lead fibrosis drug VB0004 with performance-linked incentives.